Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | BIRC2 | Q13490 | 3/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 6/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 6/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28951619 | 0.90 | POLB (0.45) | POLBSMN1; SMN2BIRC2CNR1CNR2 | |
| SCHEMBL25529988 | 0.90 | POLB (0.45) | POLBSMN1; SMN2BIRC2CNR1CNR2 | |
| SCHEMBL23883293 | 0.88 | ALDH1A1 (0.45) | FOLH1 | |
| SCHEMBL23883296 | 0.88 | ALDH1A1 (0.45) | FOLH1 | |
| SCHEMBL30211050 | 0.87 | NAAA (0.47) | POLBSMN1; SMN2BIRC2CNR1CNR2 | |
| SCHEMBL29865898 | 0.86 | SMN1; SMN2 (0.52) | POLBSMN1; SMN2BIRC2TAS1R3TAS1R1 | |
| SCHEMBL30211051 | 0.85 | POLB (0.48) | POLBSMN1; SMN2BIRC2TAS1R3TAS1R1 | |
| SCHEMBL28969225 | 0.85 | SMN1; SMN2 (0.54) | POLBSMN1; SMN2BIRC2TAS1R3TAS1R1 | |
| SCHEMBL28969227 | 0.85 | SMN1; SMN2 (0.54) | POLBSMN1; SMN2BIRC2TAS1R3TAS1R1 | |
| SCHEMBL30211056 | 0.82 | POLB (0.48) | POLBSMN1; SMN2BIRC2CNR2TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115667215-B | Broad-spectrum antiviral medicine for resisting coronavirus | 堪萨斯州立大学研究基金会 | 2026-05-19 | — | — | CN | disclosed |
| US-12583820-B2 | Broad spectrum antivirals against coronavirus | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4126816-A1 | BROAD SPECTRUM ANTIVIRALS AGAINST CORONAVIRUS | Kansas State University Research Foundation (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115667215-A | Broad-spectrum antiviral medicine for resisting coronavirus | 堪萨斯州立大学研究基金会 | 2023-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583820-B2 | Broad spectrum antivirals against coronavirus | SARS1, NSUN2, ZC3HAV1 | POLB 216/4885SMN1; SMN2 2304/4885BIRC2 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.